Data / Form D filings / Nivagen Pharmaceuticals, Inc.
Nivagen Pharmaceuticals, Inc.: Form D filings
Nivagen Pharmaceuticals, Inc., a pharmaceuticals company in Sacramento, CA, filed 3 Form D notices with the SEC between 2017 and 2023. The latest, on August 11, 2023, reports $5 million sold of a $5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3100 FITE CIRCLE, SUITE 100, Sacramento, CA, 95827
- Phone
- (916) 364-1662
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1716747
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 11, 2023 | New notice | $5,000,005 | $5,000,005 | 1 | Jun 16, 2023 | sec.gov | |
| May 20, 2020 | New notice | $15,966,462 | $15,966,462 | 7 | May 15, 2020 | sec.gov | |
| Sep 14, 2017 | New notice | $10,000,000 | $10,000,000 | 1 | Sep 7, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Dasaradhi C. Lakkaraju | Executive Officer | |
| Jaswinder Matharu | Director | |
| Gopal C. Patel | Executive Officer | |
| Jwalant Shukla | Executive Officer, Director | |
| Rob C. Hart | Director | |
| Ashish C. Sevak | Director | |
| Praneel C. Deo | Executive Officer | |
| Michael C. Kulper | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Aug 7, 2023 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Nivagen Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.